Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 7/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14938676 | 0.86 | CYP2D6 (0.53) | HPGDHSD17B10ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL29336243 | 0.76 | HTR1A (0.49) | CYP2A13CXCR4HPGDCYP2C9HSD17B10 | |
| SCHEMBL2491351 | 0.76 | CYP2A13 (0.49) | CYP2A13CXCR4HPGDCYP2C9HSD17B10 | |
| SCHEMBL19283690 | 0.75 | FGFR1 (0.46) | HPGDHSD17B10ALOX15ALDH1A1KDM4E | |
| SCHEMBL8262966 | 0.74 | DHODH (0.53) | CYP2A13CXCR4HPGDCYP2C9HSD17B10 | |
| SCHEMBL5000345 | 0.72 | CYP2A13 (0.48) | CYP2A13CXCR4HPGDCYP2C9HSD17B10 | |
| SCHEMBL11193326 | 0.71 | CYP2A13 (0.75) | CYP2A13CXCR4CYP2C9HSD17B10ALOX15 | |
| SCHEMBL23432525 | 0.70 | GAA (0.52) | CYP2A13CYP2C9HSD17B10ALOX15ALDH1A1 | |
| SCHEMBL3585287 | 0.69 | HRH3 (0.47) | HPGDHSD17B10ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL2158571 | 0.69 | SLC6A4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| US-10450320-B2 | Hexahydropyrazinotriazinone derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2019-10-22 | — | — | US | disclosed |
| US-20180362532-A1 | Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-12-20 | — | — | US | disclosed |
| EP-3157922-B1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2018-11-28 | — | — | EP | disclosed |
| EP-3386984-A1 | HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2018-10-17 | — | — | EP | disclosed |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | disclosed |
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-07-19 | — | — | US | disclosed |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BY) | 2018-06-19 | — | — | US | disclosed |
| US-9969748-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-05-15 | — | — | US | disclosed |
| EP-2935269-B1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| US-9714248-B2 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2017-07-25 | — | — | US | disclosed |
| WO-2017097871-A1 | HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2017-06-15 | — | — | WO | disclosed |
| US-20170129905-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2017-05-11 | — | — | US | disclosed |
| US-20170121337-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-05-04 | — | — | US | disclosed |
| US-20170121324-A1 | Pyrazolo-Pyridine Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2017-05-04 | — | — | US | disclosed |
| EP-2776445-B1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-08-10 | — | — | EP | disclosed |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2016-07-07 | — | — | US | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | CYP2A13 1386/4885CXCR4 2090/4885HPGD 4029/4885 |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | HAVCR2, TPMT, NFATC1 | CYP2A13 1634/4885CXCR4 460/4885HPGD 1449/4885 |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | CYP2A13 1853/4885CXCR4 1522/4885HPGD 615/4885 |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | PI4KA, PI4KB, PI4K2A | CYP2A13 2269/4885CXCR4 1244/4885HPGD 3914/4885 |
| US-20170121337-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | CYP2A13 1356/4885CXCR4 1815/4885HPGD 4089/4885 |
| US-20170129905-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | CYP2A13 1386/4885CXCR4 2090/4885HPGD 4029/4885 |
| US-10450320-B2 | Hexahydropyrazinotriazinone derivatives as kinase inhibitors | PI4KA, PI4KB, PI4K2B | CYP2A13 1876/4885CXCR4 1992/4885HPGD 3783/4885 |
| US-20180362532-A1 | Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors | PI4KA, PI4KB, PI4K2B | CYP2A13 1876/4885CXCR4 1992/4885HPGD 3783/4885 |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | PI4KB, PI4KA, PI4K2B | CYP2A13 1356/4885CXCR4 1815/4885HPGD 4089/4885 |
| US-20170121324-A1 | Pyrazolo-Pyridine Derivatives as Kinase Inhibitors | PI4KA, PI4KB, PI4K2A | CYP2A13 2269/4885CXCR4 1244/4885HPGD 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.